Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
42.04
+1.39 (3.42%)
Nov 21, 2024, 11:44 AM EST - Market open
Protagonist Therapeutics Employees
Protagonist Therapeutics had 112 employees as of December 31, 2023. The number of employees increased by 7 or 6.67% compared to the previous year.
Employees
112
Change (1Y)
7
Growth (1Y)
6.67%
Revenue / Employee
$2,891,027
Profits / Employee
$1,525,438
Market Cap
2.51B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Ardent Health Partners | 23,000 |
Zai Lab | 2,175 |
iRhythm Technologies | 2,000 |
Twist Bioscience | 919 |
LeMaitre Vascular | 630 |
Arrowhead Pharmaceuticals | 525 |
Catalyst Pharmaceuticals | 167 |
Scholar Rock Holding | 150 |
PTGX News
- 2 days ago - Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate - Accesswire
- 13 days ago - Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Accesswire
- 15 days ago - Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting - Accesswire
- 2 months ago - Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines - Benzinga
- 2 months ago - Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 - Accesswire
- 3 months ago - Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Accesswire
- 4 months ago - Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor - Accesswire
- 4 months ago - Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024 - Accesswire